Romiplostim is a fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor.
- Mechanism
- Curator reviewed
Romiplostim is a thrombopoietin receptor agonist that activates intracellular transcriptional pathways via c-Mpl to increase production of platelets. It also works similarly to thrombopoietin (TPO), an endogenous glycoprotein hormone that regulates the production of platelets in the bone marrow.
- Primary indication
- Treatment of chronic immune thrombocytopenic purpura.Curator reviewed · 2 structured indications
- Formula / weight
- C2634H4086N722O790S18 · 59000.0 Da
- First approval
- Canada, 2009 · United States, 2008 · European Union, 2016
- Code names
- AMG-531
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Romiplostim, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account